Compare NP & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NP | IDYA |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.6B |
| IPO Year | 2025 | 2019 |
| Metric | NP | IDYA |
|---|---|---|
| Price | $31.71 | $36.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 16 |
| Target Price | $28.17 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 714.3K | 691.4K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | ★ $218,710,000.00 |
| Revenue This Year | $25.84 | N/A |
| Revenue Next Year | $15.80 | $201.05 |
| P/E Ratio | $200.56 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $14.78 | $23.23 |
| 52 Week High | $35.15 | $40.58 |
| Indicator | NP | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 52.25 | 52.85 |
| Support Level | $23.52 | $33.23 |
| Resistance Level | $34.43 | $37.82 |
| Average True Range (ATR) | 1.57 | 1.17 |
| MACD | -0.13 | -0.04 |
| Stochastic Oscillator | 25.78 | 60.91 |
Neptune Insurance Holdings Inc is a high-growth, profitable, data-driven MGA that offers residential and commercial insurance products, including primary flood insurance, excess flood insurance and parametric earthquake insurance, distributed through a nationwide network of agencies in the United States. The company underwrites and administers the issuance of insurance policies on behalf of a diverse panel of insurance and reinsurance companies and does not take any balance sheet insurance risk or have claims handling responsibility relating to the policies it sells.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.